Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GCK | P35557 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | CCR9 | P51686 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 5/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9540049 | 0.77 | RECQL (0.79) | RECQLGCKFADS1NOS2RAB9A | |
| SCHEMBL2616485 | 0.77 | CCR9 (0.52) | SORT1CCR9GRM5GBA1RAB9A | |
| SCHEMBL23366592 | 0.76 | CNR2 (0.59) | SORT1P2RX7GRM5GBA1RAB9A | |
| SCHEMBL21449309 | 0.76 | NR4A2 (0.53) | SORT1CCR9GRM5 | |
| SCHEMBL342047 | 0.76 | RECQL (0.58) | RECQLGCKCCR9RAB9AL3MBTL1 | |
| SCHEMBL31366584 | 0.76 | RECQL (0.58) | RECQLGCKCCR9RAB9AL3MBTL1 | |
| SCHEMBL1958309 | 0.75 | P2RX7 (0.62) | P2RX7GRM5NOS2GBA1RAB9A | |
| SCHEMBL7508110 | 0.74 | ENPP2 (0.46) | P2RX7 | |
| SCHEMBL25633942 | 0.73 | RECQL (0.58) | RECQLGCKFADS1NOS2RAB9A | |
| SCHEMBL27860 | 0.73 | MAPT (0.55) | RECQLFADS1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| EP-1798223-A2 | Aryl sulfonamides | ChemoCentryx Inc (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| CN-1711257-A | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-12-21 | — | — | CN | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6939885-B2 | Aryl sulfonamides | CHEMOCENTRYX (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1562940-A2 | ARYL SULFONAMIDES | ChemoCentryx Inc (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050165067-A1 | Aryl sulfonamides | CHEMOCENTRYX | 2005-07-28 | — | — | US | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040171654-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004046092-A2 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20040171654-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20050165067-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | RECQL 4746/4885GCK 3574/4885SORT1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.